Alector - ALEC Year-over-year earnings per share growth for the last twelve months
Compliance with biowaste disposal standards is a key market requirement for Alector, Inc. Quarterly growth in net earnings per share demonstrates the company's momentum, with 431.20 representing the current level. Business stability is supported by autonomous power systems in San Francisco and the combination of robotic molecular screening with expert physician oversight during clinical trials.
Summary analytical data breakdowns for Alector, Inc. (ALEC)
- share price and consensus valuation forecast:
- issuer market value details:
- book capitalization data:
- company liabilities and liquidity data:
Total Debt to Capital Alector, Inc.|ALEC - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity alector.com|ALEC - Company Aggregate Debt|Debts to Book Capitalization Alector Therapeutics|ALEC - Company Long-Term Liabilities|Company Current Liabilities Alector|Quick Ratio alector.com
- earnings and market multiples details:
ALEC - Net Profit|Expected Profit Alector, Inc.|ALEC - Price to Earnings Ratio|Forward P/E Multiple alector.com|ALEC - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Alector Therapeutics|ALEC - Operating profit before deduction of amortization|Earnings per share for the last twelve months Alector|ALEC - Earnings per share for the last 12 months|Quarterly EPS earnings growth alector.com|ALEC - Earnings per share growth rate in current year|Expected earnings per share growth for next year Alector, Inc.
Summary company analysis:Alector Inc. - ALEC
Investors are evaluating Alector, Inc. (ALEC) through the lens of the effectiveness of its neurodegenerative disease therapy development. This metric captures the rate of change in quarterly net earnings per share compared to the previous period. By analyzing the relative growth of quarterly EPS, one can determine the dynamics of operating profitability. For a biotech company, this vector reflects the success of commercializing innovations in microglia activation. The upward trend confirms the business's financial stability.
Main competitors
BIIB (Biogen) - Year-over-year net earnings per share growth for the last 12 months|NBIX: Year-over-year earnings per share growth rate for the last twelve months|Year-over-year earnings per share growth for the last twelve months Regencell|Earnings per share growth in annualized terms for the last twelve months Axsome Corp AXSM|Year-over-year earnings per share growth for the last twelve months ACADIA Pharmaceuticals (ACAD)|XENE (xenon-pharma.com) - Year-over-year earnings per one share growth for the last 12 months|Viking Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months SUPN|Catalyst Pharmaceuticals Inc - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Denali Corp DNLI|Harmony Biosciences (HRMY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months BHVN|AMLX (Amylyx Pharmaceuticals, Inc.) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Trevi Therapeutics Inc (TRVI)|Year-over-year net earnings per share growth for the last 12 months PRAX (Praxis Medicines)|Year-over-year net earnings per share change for the last twelve months Anavex Life Sciences Corp|Quarterly EPS earnings growth CBLL (CeriBell, Inc.)|Quarterly EPS earnings growth prothena.com PRTA|ANNX - Year-over-year earnings per share growth for the last twelve months|OMER: Year-over-year earnings per share growth for the last twelve months|NGNE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months AC Immune Inc (ACIU)|VYGR (Voyager Therapeutics) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months neumoratx.com (NMRA)|Year-over-year earnings per share growth for the last twelve months Scilex (SCLX)|Tevogen Bio Holdings Inc. - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth ACOG (Alpha Cognition Inc.)|cogrx.com (CGTX) - Earnings per share growth in annualized terms for the last twelve months|IKT: Year-over-year net earnings per share growth for the last 12 months|SAVA - Quarterly EPS earnings growth|assertiotx.com (ASRT) - Year-over-year earnings per share growth for the last twelve months|Coya Therapeutics - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months VistaGen Therapeutics, Inc.|Earnings per share growth in annualized terms for the last twelve months Ovid Rx OVID|Quarterly EPS earnings growth ABOS|Quarterly EPS earnings growth cervomed.com (CRVO)|Year-over-year earnings per share growth for the last twelve months Alterity Therapeutics Limited ATHE|Clene Inc - Year-over-year earnings per share growth for the last twelve months|PepGen Corp - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months jupiterneurosciences.com|RLMD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months annovisbio.com|Year-over-year net earnings per share growth for the last 12 months GRCE|AIFF (Firefly Neuroscience, Inc.) - Year-over-year earnings per share growth rate for the last twelve months|Year-over-year earnings per share growth for the last twelve months Klotho Neurosciences Inc (KLTO)|NRSN - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Reviva Pharmaceuticals RVPH|Year-over-year earnings per one share growth for the last 12 months MTVA|NRXS: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months HSDT (Helius Medical)|PASG: Quarterly EPS earnings growth|NEUP - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Minerva Neurosciences|Year-over-year earnings per share growth for the last 12 months ATHA (athira.com)|Quarterly EPS earnings growth ADXN|Year-over-year net earnings per share growth for the last 12 months alzamend.com ALZN|Cyclerion Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Protagenic Therapeutics Inc. (PTIX)|Pasithea - Quarterly EPS earnings growth|CRGT - Quarterly EPS earnings growth|Avenue Therapeutics, Inc. (ATXI) - Year-over-year earnings per share growth for the last twelve months|BCLI (Brainstorm Cell Therapeutics Inc.) - Year-over-year earnings per share growth for the last twelve months|CARA (Cara Therapeutics, Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Chromocell CHRO|Quarterly EPS earnings growth ELYM|Year-over-year net earnings per share growth for the last 12 months intracellulartherapies.com ITCI|Year-over-year earnings per share growth for the last twelve months Longboard Pharmaceuticals, Inc. LBPH|MRNS: Year-over-year earnings per share growth for the last 12 months|NKGen - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months NeuroBo Pharma|SAGE (Sage Therapeutics, Inc.) - Year-over-year net earnings per share growth for the last 12 months|synaptogen.com (SNPX) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Trevena|VIGL: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Anew Medical, Inc. (WENA)|CERE - Earnings per share growth in annualized terms for the last twelve months
